Route Comparison: Capsules vs
What the Research Says About Safety Clinical studies on AOD9604 indicate that the peptide is generally welltolerated: In human trials, no significant adverse effects were reported at doses up to 1 mg/day (safety summary) Unlike growth hormone therapies, AOD9604 does not meaningfully elevate IGF1 levels (human data), which may reduce the risk of unwanted growthrelated side effects
If youre looking for other ways to support weight loss and are curious about peptides, the top options to consider are proven GLP-1 drugs, such as Ozempic or Wegovynot GHK-Cu
Specifically, the decrease in SIRT1 levels, inhibition of its activity, or generation of mutations that lower its activity have been linked to intestinal inflammation and colitis in human and rodent models (Melhem et al., 2016
10.1016/S0954-6111(03)00026-X 80 GronebergD